Wire · opportunities
Telix and ITM merge in $1.65B deal poised to expand radiopharmaceutical development ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Telix Pharmaceuticals is merging with ITM Isotope Technologies Munich in a $1.65 billion deal to combine radioisotope manufacturing with radiopharmaceutical development, aiming to control the supply chain from isotope production to patient treatment and expanding their commercial reach to over 65 countries.
This Wire brief sits within Fusion42's coverage of Health, and 4 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You face a new market leader in radiopharmaceuticals as Telix moves to control both production and therapy development. If you work in radiopharmaceutical or isotope supply, this merger reshapes who your competitors and partners may be.
◆ Coverage
4 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics